First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: Results from an open, prospective, multicentre trial

Annamaria Colao, Rosario Pivonello, Francesca Rosato, Patrizia Tita, Ernesto De Menis, Antonina Barreca, Roberto Ferrara, Franco Mainini, Maura Arosio, Gaetano Lombardi

Research output: Contribution to journalArticle

Abstract

Background: The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor. Objective: To investigate the clinical application of octreotide-LAR as primary treatment in newly diagnosed patients with GH-secreting pituitary tumours. Design: Open, prospective, multicentre, 24-week follow-up study. Patients: Thirty-four patients were enrolled (20 men, 14 women; mean age, 50 years); 13 had microadenoma [median tumour volume 327 mm3 (range 31-629 mm 3)], 21 had macroadenoma [median tumour volume 1325 mm3 (range 503-11583 mm3)]. Interventions: Octreotide-LAR at the dosage of 20 mg every 28 days for the first 12 weeks increased to 30 mg every 28 days to control GH and/or IGF-I excess in 20 patients (64.7%). Main outcome measures: Primary endpoints were control of GH (fasting <2.5 μg/l) and IGF-I secretion (gender- and age-normalized) and presence and entity of tumour mass shrinkage. Secondary endpoint was improvement of symptoms score. Results: In patients with micro- and macroadenomas GH levels decreased to <2.5 μg/l in 84.6% and 45%, serum IGF-I levels normalized for age and gender in 61.5% and 35% of cases. Failure in achieving either GH <2.5 μg/l or normal IGF-I levels was found in none of the patients with micro- and in 45% of patients with macroadenoma. Median tumour volume was reduced by 54% (range: -90% to +350%) in micro- and by 49% (range -94% to -14%) in macroadenomas. Headache, perspiration and osteo-arthralgias disappeared in 21%, paresthesias in 38%, fatigue in 26% and carpal tunnel syndrome in 15%. The treatment was well tolerated: more frequent adverse events were gastrointestinal (in 44%). Conclusions: In both patients with micro- or macroadenoma, primary octreotide-LAR treatment controls hormone excess, induces tumour shrinkage and improves symptoms of acromegaly with limited side effects and can be therefore successfully employed in patients with contraindications for surgery or in those who refuse surgery.

Original languageEnglish
Pages (from-to)342-351
Number of pages10
JournalClinical Endocrinology
Volume64
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Acromegaly
Octreotide
Multicenter Studies
Hormones
Neoplasms
Insulin-Like Growth Factor I
Tumor Burden
Therapeutics
Carpal Tunnel Syndrome
Paresthesia
Arthralgia
Pituitary Neoplasms
Fatigue
Headache
Fasting
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Endocrinology

Cite this

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly : Results from an open, prospective, multicentre trial. / Colao, Annamaria; Pivonello, Rosario; Rosato, Francesca; Tita, Patrizia; De Menis, Ernesto; Barreca, Antonina; Ferrara, Roberto; Mainini, Franco; Arosio, Maura; Lombardi, Gaetano.

In: Clinical Endocrinology, Vol. 64, No. 3, 03.2006, p. 342-351.

Research output: Contribution to journalArticle

Colao, Annamaria ; Pivonello, Rosario ; Rosato, Francesca ; Tita, Patrizia ; De Menis, Ernesto ; Barreca, Antonina ; Ferrara, Roberto ; Mainini, Franco ; Arosio, Maura ; Lombardi, Gaetano. / First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly : Results from an open, prospective, multicentre trial. In: Clinical Endocrinology. 2006 ; Vol. 64, No. 3. pp. 342-351.
@article{cafbfa0bb7fd4a7485bd516a87d0b424,
title = "First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: Results from an open, prospective, multicentre trial",
abstract = "Background: The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor. Objective: To investigate the clinical application of octreotide-LAR as primary treatment in newly diagnosed patients with GH-secreting pituitary tumours. Design: Open, prospective, multicentre, 24-week follow-up study. Patients: Thirty-four patients were enrolled (20 men, 14 women; mean age, 50 years); 13 had microadenoma [median tumour volume 327 mm3 (range 31-629 mm 3)], 21 had macroadenoma [median tumour volume 1325 mm3 (range 503-11583 mm3)]. Interventions: Octreotide-LAR at the dosage of 20 mg every 28 days for the first 12 weeks increased to 30 mg every 28 days to control GH and/or IGF-I excess in 20 patients (64.7{\%}). Main outcome measures: Primary endpoints were control of GH (fasting <2.5 μg/l) and IGF-I secretion (gender- and age-normalized) and presence and entity of tumour mass shrinkage. Secondary endpoint was improvement of symptoms score. Results: In patients with micro- and macroadenomas GH levels decreased to <2.5 μg/l in 84.6{\%} and 45{\%}, serum IGF-I levels normalized for age and gender in 61.5{\%} and 35{\%} of cases. Failure in achieving either GH <2.5 μg/l or normal IGF-I levels was found in none of the patients with micro- and in 45{\%} of patients with macroadenoma. Median tumour volume was reduced by 54{\%} (range: -90{\%} to +350{\%}) in micro- and by 49{\%} (range -94{\%} to -14{\%}) in macroadenomas. Headache, perspiration and osteo-arthralgias disappeared in 21{\%}, paresthesias in 38{\%}, fatigue in 26{\%} and carpal tunnel syndrome in 15{\%}. The treatment was well tolerated: more frequent adverse events were gastrointestinal (in 44{\%}). Conclusions: In both patients with micro- or macroadenoma, primary octreotide-LAR treatment controls hormone excess, induces tumour shrinkage and improves symptoms of acromegaly with limited side effects and can be therefore successfully employed in patients with contraindications for surgery or in those who refuse surgery.",
author = "Annamaria Colao and Rosario Pivonello and Francesca Rosato and Patrizia Tita and {De Menis}, Ernesto and Antonina Barreca and Roberto Ferrara and Franco Mainini and Maura Arosio and Gaetano Lombardi",
year = "2006",
month = "3",
doi = "10.1111/j.1365-2265.2006.02467.x",
language = "English",
volume = "64",
pages = "342--351",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly

T2 - Results from an open, prospective, multicentre trial

AU - Colao, Annamaria

AU - Pivonello, Rosario

AU - Rosato, Francesca

AU - Tita, Patrizia

AU - De Menis, Ernesto

AU - Barreca, Antonina

AU - Ferrara, Roberto

AU - Mainini, Franco

AU - Arosio, Maura

AU - Lombardi, Gaetano

PY - 2006/3

Y1 - 2006/3

N2 - Background: The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor. Objective: To investigate the clinical application of octreotide-LAR as primary treatment in newly diagnosed patients with GH-secreting pituitary tumours. Design: Open, prospective, multicentre, 24-week follow-up study. Patients: Thirty-four patients were enrolled (20 men, 14 women; mean age, 50 years); 13 had microadenoma [median tumour volume 327 mm3 (range 31-629 mm 3)], 21 had macroadenoma [median tumour volume 1325 mm3 (range 503-11583 mm3)]. Interventions: Octreotide-LAR at the dosage of 20 mg every 28 days for the first 12 weeks increased to 30 mg every 28 days to control GH and/or IGF-I excess in 20 patients (64.7%). Main outcome measures: Primary endpoints were control of GH (fasting <2.5 μg/l) and IGF-I secretion (gender- and age-normalized) and presence and entity of tumour mass shrinkage. Secondary endpoint was improvement of symptoms score. Results: In patients with micro- and macroadenomas GH levels decreased to <2.5 μg/l in 84.6% and 45%, serum IGF-I levels normalized for age and gender in 61.5% and 35% of cases. Failure in achieving either GH <2.5 μg/l or normal IGF-I levels was found in none of the patients with micro- and in 45% of patients with macroadenoma. Median tumour volume was reduced by 54% (range: -90% to +350%) in micro- and by 49% (range -94% to -14%) in macroadenomas. Headache, perspiration and osteo-arthralgias disappeared in 21%, paresthesias in 38%, fatigue in 26% and carpal tunnel syndrome in 15%. The treatment was well tolerated: more frequent adverse events were gastrointestinal (in 44%). Conclusions: In both patients with micro- or macroadenoma, primary octreotide-LAR treatment controls hormone excess, induces tumour shrinkage and improves symptoms of acromegaly with limited side effects and can be therefore successfully employed in patients with contraindications for surgery or in those who refuse surgery.

AB - Background: The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor. Objective: To investigate the clinical application of octreotide-LAR as primary treatment in newly diagnosed patients with GH-secreting pituitary tumours. Design: Open, prospective, multicentre, 24-week follow-up study. Patients: Thirty-four patients were enrolled (20 men, 14 women; mean age, 50 years); 13 had microadenoma [median tumour volume 327 mm3 (range 31-629 mm 3)], 21 had macroadenoma [median tumour volume 1325 mm3 (range 503-11583 mm3)]. Interventions: Octreotide-LAR at the dosage of 20 mg every 28 days for the first 12 weeks increased to 30 mg every 28 days to control GH and/or IGF-I excess in 20 patients (64.7%). Main outcome measures: Primary endpoints were control of GH (fasting <2.5 μg/l) and IGF-I secretion (gender- and age-normalized) and presence and entity of tumour mass shrinkage. Secondary endpoint was improvement of symptoms score. Results: In patients with micro- and macroadenomas GH levels decreased to <2.5 μg/l in 84.6% and 45%, serum IGF-I levels normalized for age and gender in 61.5% and 35% of cases. Failure in achieving either GH <2.5 μg/l or normal IGF-I levels was found in none of the patients with micro- and in 45% of patients with macroadenoma. Median tumour volume was reduced by 54% (range: -90% to +350%) in micro- and by 49% (range -94% to -14%) in macroadenomas. Headache, perspiration and osteo-arthralgias disappeared in 21%, paresthesias in 38%, fatigue in 26% and carpal tunnel syndrome in 15%. The treatment was well tolerated: more frequent adverse events were gastrointestinal (in 44%). Conclusions: In both patients with micro- or macroadenoma, primary octreotide-LAR treatment controls hormone excess, induces tumour shrinkage and improves symptoms of acromegaly with limited side effects and can be therefore successfully employed in patients with contraindications for surgery or in those who refuse surgery.

UR - http://www.scopus.com/inward/record.url?scp=33644944535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644944535&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2006.02467.x

DO - 10.1111/j.1365-2265.2006.02467.x

M3 - Article

C2 - 16487447

AN - SCOPUS:33644944535

VL - 64

SP - 342

EP - 351

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -